[ad_1]
A Japanese researcher announced this Friday. Transplanted induced pluripotent stem cells (iPS) In the brain of a sick patient Parkinson's disease, The world's first trial.
A team of Kyoto University put 2.4 million people. iPS cells It can produce any kind of cells in the left part of the brain for 3 hours performed in October.
A statement from the University of Kyoto said that a 50-year-old man will be in good health and under surveillance for two years.
The viability of the transplanted cells for two years was closely monitored. Photo: Pixabay
If problems occur within the next six months, the researchers will insert 2.4 million additional cells into the right side of the brain.
Healthy donor iPS cells are supposed to develop into neurons that are generated. Dopamine, A neurotransmitter that intervenes in the regulation of athletic performance.
Kyoto University announced in July that it will conduct clinical trials with seven people between the ages of 50 and 69.
The new investigation is to reverse the evil. Theme image. Photo: Pixabay
Parkinson's disease is characterized by regression of nerve cells that progressively worsens symptoms such as progression, muscle stiffness, and loss of ability to move the body.
According to the Foundation, it affects more than 10 million people in the world. Parkinson's disease American. Currently available therapies "improve symptoms without slowing the progression of the disease.
The new investigation is to reverse the evil.
Parkinson's disease is characterized by nerve cell degeneration. Illustration image. Photo: Pixabay
In a study published in the scientific journal Nature at the end of August 2017 before clinical trials in humans, experiments were conducted with monkeys with human-derived stem cells that could improve the ability of primates to migrate from Parkinson's disease .
The survival level of the transplanted cells for 2 years was closely monitored by injecting into the primate brain and no tumor was found.
Induced pluripotent stem cells (iPS) produce four genes by virtue of reducing embryonic adult cells to embryonic states (usually inactive in adults). This genetic manipulation returns the ability to produce certain cells depending on where they are implanted.
The use of iPS cells does not cause serious ethical problems unlike stem cells from human embryos.
[ad_2]
Source link
